|
**Overview**: Chromosome Analysis Chorionic Villus Panel**Introduction**: The Chromosome Analysis Chorionic Villus Panel is a diagnostic tool designed to screen for fetal chromosomal disorders using chorionic villus samples. In India, first-trimester prenatal diagnosis via CVS is preferred for early detection of aneuploidies and structural rearrangements (yield similar to amniocentesis, faster results). High burden of chromosomal anomalies in high-risk pregnancies, under-screening in rural areas, limited fetal medicine access, delayed results leading to late decisions. Per cytogenetics practices aligned with ICMR and FOGSI guidelines, the test employs karyotyping on cultured CVS over 1-2 days with high accuracy, valuable for rapid first-trimester evaluation. This diagnostic falls under prenatal screening and targets high-risk pregnancies (maternal age, abnormal NT, positive screening), addressing accurate detection to guide counseling. With elevated morbidity due to under-screening, the test supports public health efforts by enabling precise identification and reducing birth defects. Its CVS-based approach ensures reliable fetal cell analysis.**Other Names**: CVS Karyo Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: CVS karyotyping standard; in India, key in early prenatal diagnosis.**Purpose**: The test performs 2 parameters including fetal karyotype to guide detection of chromosomal abnormalities, identify anomalies, inform counseling.**Test Parameters**: 1. Fetal Karyotype, 2. Chromosomal Abnormalities.**Pretest Condition**: No fasting required; patients should have high-risk pregnancy indicators.**Specimen**: 10 mg chorionic villus in sterile medium, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate culture is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for karyotyping).**Medical History**: Patients should provide details on maternal age, ultrasound findings, serum screening, family genetic history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of fetal abnormalities including termination decisions, benefits of detection, and minimal discomfort from CVS procedure.**Procedural Considerations**: The test involves sample processing using karyotyping (G-banding) by trained personnel to ensure sterile technique, culture villi, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell growth can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal fetal karyotype indicates chromosomal disorder, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Fetal medicine specialists or geneticists should be consulted for management.**Additional Supporting Tests**: CMA or FISH for confirmation.**Test Limitations**: Detects only gross abnormalities; comprehensive approach required.**References**: Indian Journal of Medical Genetics 2024, Prenatal Studies India 2023. |
